Regulatory functions of TRAIL in hematopoietic progenitors: Human umbilical cord blood and murine bone marrow transplantation

Leukemia

Volumn 24, Issue 7, 2010, Pages 1325-1334

  Mizrahi, K ^a   Stein, J ^a   Pearl Yafe, M ^a   Kaplan, O ^b   Yaniv, I ^a   Askenasy, N ^a  

^a Schneider Childrens Medical Center of Israel   (Ireland)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

hematopoietic progenitors; TRAIL; transplantation; umbilical cord blood

Indexed keywords

CD19 ANTIBODY; CD3 ANTIGEN; CD33 ANTIGEN; DEATH RECEPTOR 5; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEM CELL FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL CULTURE; CLONOGENIC ASSAY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPOPLASIA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL CORD BLOOD; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW; C57BL MOUSE; CFU COUNTING; DRUG EFFECTS; FETUS BLOOD; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ANIMALS; APOPTOSIS; BONE MARROW; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; FETAL BLOOD; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; STEM CELL FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77954659352     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.97     Document Type: Article

References (49)

1. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-756.
2. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004;201:331-340.
3. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006;17:245-257.
4. Secchiero P, Zauli G. Tumor-necrosis-factor-related apoptosisinducing ligand and the regulation of hematopoiesis. Curr Opin Hematol 2008;15:42-48.
5. Carlo-Stella C, Lavazza C, Locatelli A, Viganò L, Gianni AM, Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res 2007;13:2313-2317.
6. Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 2008;49:27-35.
7. Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009;35:280-288.
8. Song K, Benhaga N, Anderson RL, Khosravi-Far R. Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res 2006;66:6304-6311.
9. Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, Milanesi M et al. Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 2006;17:1225-1240.
10. Kim SM, Lim JY, Park SI, Jeong CH, Oh JH, Jeong M et al. Gene therapy using TRAIL-secreting human umbilical cord bloodderived mesenchymal stem cells against intracranial glioma. Cancer Res 2008;68:9614-9623.
11. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 2009;106:4822-4827.
12. Dempsey PW, Doyle SE, He JQ, Cheng G. The signalling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14:193-209.
13. Gaur U, Aggarwal BB. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003;66:1403-1408.
14. Ware CF. The TNF superfamily. Cytokine Growth Factor Rev 2003;14:181-184.
15. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-1475.
16. Wilson NS, Dixit V, Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009;10:348-355.
17. De Maria R, Zeuner A, Eramo A, Domenichelli C, Bonci D, Grignani F et al. Negative regulation of erythropoiesis by caspasemediated cleavage of GATA-1. Nature 1999;401:489-493.
18. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000;95:3716-3724.
19. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Zauli G. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004;103:517-522.
20. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999;59:2770-2775.
21. Schneider P, Olson D, Tardivel A, Browning B, Lugovskoy A, Gong D et al. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2003;278:5444-5454.
22. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999;13:1817-1824.
23. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002;16:67-73.
24. Lee NS, Cheong HJ, Kim SJ, Kim SE, Kim CK, Lee KT et al. Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. Leukemia 2003;17:1375-1383.
25. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163. (Pubitemid 29068521)
26. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000;97:1754-1759.
27. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
28. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005;166:557-563.
29. Kakagianni T, Giannakoulas NC, Thanopoulou E, Galani A, Michalopoulou S, Kouraklis-Symeonidis A et al. A probable role for TRAIL-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res 2006;30:713-721.
30. Greil R, Anether G, Johrer K, Tinhofer I. Tuning the rheostat of the myelopoietic system via Fas and TRAIL. Crit Rev Immunol 2003;23:301-322.
31. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004;18:1176-1199.
32. Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I et al. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells 2007;25:3194-3203.
33. Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I et al. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol 2007;35:1601-1612.
34. Harris DT, LoCascio J, Besencon FJ. Analysis of the alloreactive capacity of human umbilical cord blood: implications for graftversus-host disease. Bone Marrow Transplant 1994;14:545-553.
35. Song K, Chen Y, Göke R, Wilmen A, Seidel C, Göke A et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000;191:1095-1104.
36. Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J et al. T cells require TRAIL for optimal graft-versustumor activity. Nat Med 2002;8:1433-1437.
37. Eaves C, Glimm H, Eisterer W, Audet J, Maguer-Satta V, Piret J. Characterization of human hematopoietic cells with short-lived in vivo repopulating activity. Ann NY Acad Sci 2001;938:63-70.
38. Manz MG. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 2007;26:537-541.
39. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002;100:2421-2429.
40. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-1354.
41. Zauli G, Rimondi E, Stea S, Baruffaldi F, Stebel M, Zerbinati C et al. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 2008;214:117-125.
42. Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells 2008;26:2955-2963.
43. Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008;127:286-297.
44. BaumannS, Zhu JY, Giaisi M, Treiber MK, Mahlknecht U, Krammer PH et al. Wogonin sensitizes resistant malignant cells to TNF\ {alpha}-and TRAIL-induced apoptosis. Blood 2006;108:3700-3706.
45. Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H et al. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells 2007;25:1448-1455.
46. Burroughs L, Storb R. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graftversus-leukemia effects from graft-versus-host disease. Curr Opin Hematol 2005;12:45-54.
47. Resnick IB, Shapira MY, Slavin S. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases. Transpl Immunol 2005;14:207-219.
48. Yaniv I, Stein J. Reduced-intensity conditioning in children: a reappraisal in 2008. Bone Marrow Transplant 2008;41(Suppl 2):S18-S22.
49. Yaniv I, Ash S, Farkas DL, Askenasy N, Stein J. Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 2009;33:255-259.